Dimensional Fund Advisors LP Buys 81,083 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

Dimensional Fund Advisors LP increased its stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 111.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 153,758 shares of the company’s stock after acquiring an additional 81,083 shares during the period. Dimensional Fund Advisors LP’s holdings in Monte Rosa Therapeutics were worth $575,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its stake in shares of Monte Rosa Therapeutics by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,096,787 shares of the company’s stock worth $35,933,000 after purchasing an additional 155,880 shares in the last quarter. American Century Companies Inc. raised its position in Monte Rosa Therapeutics by 46.0% during the second quarter. American Century Companies Inc. now owns 49,410 shares of the company’s stock worth $185,000 after acquiring an additional 15,562 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Monte Rosa Therapeutics by 92.5% in the first quarter. Acadian Asset Management LLC now owns 55,548 shares of the company’s stock valued at $390,000 after acquiring an additional 26,687 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Monte Rosa Therapeutics by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 1,635,829 shares of the company’s stock valued at $11,533,000 after acquiring an additional 47,412 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Monte Rosa Therapeutics by 16.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 109,864 shares of the company’s stock worth $411,000 after purchasing an additional 15,845 shares during the last quarter. 79.96% of the stock is owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Stock Performance

Shares of GLUE stock opened at $4.93 on Monday. The company has a market capitalization of $249.02 million, a price-to-earnings ratio of -1.96 and a beta of 1.43. Monte Rosa Therapeutics, Inc. has a 52 week low of $2.44 and a 52 week high of $8.84. The company has a 50-day simple moving average of $5.45 and a 200 day simple moving average of $5.08.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.07. The firm had revenue of $4.70 million during the quarter, compared to analyst estimates of $3.20 million. Sell-side analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.89 EPS for the current year.

Insider Transactions at Monte Rosa Therapeutics

In related news, major shareholder Versant Venture Capital Vi, L. sold 1,132,566 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $6.53, for a total value of $7,395,655.98. Following the transaction, the insider now directly owns 5,099,336 shares in the company, valued at approximately $33,298,664.08. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 1,683,732 shares of company stock valued at $10,704,135. 6.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Monte Rosa Therapeutics in a research note on Thursday, September 12th. Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 price objective on shares of Monte Rosa Therapeutics in a research report on Friday, June 28th. Finally, Wells Fargo & Company reduced their target price on Monte Rosa Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Monday, August 12th.

Monte Rosa Therapeutics Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.